BR112018012524A2 - anticorpos variantes para conjugação sítio-específica - Google Patents
anticorpos variantes para conjugação sítio-específicaInfo
- Publication number
- BR112018012524A2 BR112018012524A2 BR112018012524A BR112018012524A BR112018012524A2 BR 112018012524 A2 BR112018012524 A2 BR 112018012524A2 BR 112018012524 A BR112018012524 A BR 112018012524A BR 112018012524 A BR112018012524 A BR 112018012524A BR 112018012524 A2 BR112018012524 A2 BR 112018012524A2
- Authority
- BR
- Brazil
- Prior art keywords
- site
- variant antibodies
- specific conjugation
- antibodies
- variant
- Prior art date
Links
- 230000021615 conjugation Effects 0.000 title 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
os anticorpos variantes com substituições de cisteína em posições selecionadas na região fc podem ser conjugados através do grupo tiol da cisteína substituída.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562270245P | 2015-12-21 | 2015-12-21 | |
PCT/US2016/067663 WO2017112624A1 (en) | 2015-12-21 | 2016-12-20 | Variant antibodies for site-specific conjugation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018012524A2 true BR112018012524A2 (pt) | 2018-12-11 |
Family
ID=57944491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018012524A BR112018012524A2 (pt) | 2015-12-21 | 2016-12-20 | anticorpos variantes para conjugação sítio-específica |
Country Status (13)
Country | Link |
---|---|
US (1) | US20180362619A1 (pt) |
EP (1) | EP3394096A1 (pt) |
JP (1) | JP2019505575A (pt) |
KR (1) | KR20180089433A (pt) |
CN (1) | CN108431034A (pt) |
AU (1) | AU2016377371A1 (pt) |
BR (1) | BR112018012524A2 (pt) |
CA (1) | CA3008678A1 (pt) |
EA (1) | EA201891482A1 (pt) |
IL (1) | IL260049A (pt) |
MX (1) | MX2018007479A (pt) |
SG (1) | SG11201805150QA (pt) |
WO (1) | WO2017112624A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11623965B2 (en) | 2017-08-16 | 2023-04-11 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
AU2018346264A1 (en) | 2017-10-03 | 2020-04-23 | Merck Patent Gmbh | Cysteine engineered antigen-binding molecules |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126250A (en) | 1988-09-28 | 1992-06-30 | Eli Lilly And Company | Method for the reduction of heterogeneity of monoclonal antibodies |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
EP0862553A4 (en) | 1995-10-03 | 1999-02-03 | Scripps Research Inst | CBI ANALOG OF CC-1065 AND THE DUOCARMYCINES |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
JP4118462B2 (ja) | 1999-07-19 | 2008-07-16 | 株式会社リコー | 携帯電子機器 |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
CN1638800A (zh) | 2002-01-09 | 2005-07-13 | 米德列斯公司 | 抗cd30的人类单克隆抗体 |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
EA009285B1 (ru) | 2003-05-14 | 2007-12-28 | Иммуноджен, Инк. | Композиция конъюгированного лекарственного средства |
UY28424A1 (es) | 2003-07-22 | 2005-02-28 | Schering Ag | Anticuerpos rgi y usos de los mismos. |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
KR101374514B1 (ko) | 2003-12-10 | 2014-03-13 | 메다렉스, 인코포레이티드 | Ip―10 항체 및 그의 용도 |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US7778814B2 (en) | 2004-03-30 | 2010-08-17 | Siemens Aktiengesellschaft | Method and device for simulating an automation system |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
AU2006214031A1 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (PSMA) |
CA2598454C (en) | 2005-02-18 | 2013-04-09 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
US20100104564A1 (en) | 2005-03-29 | 2010-04-29 | Genevieve Hansen | Altered Antibody Fc Regions and Uses Thereof |
CA2605781A1 (en) | 2005-05-09 | 2007-04-12 | Glycart Biotechnology Ag | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
US8097703B2 (en) | 2005-06-20 | 2012-01-17 | Medarex, Inc. | CD19 antibodies and their uses |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
EA016186B1 (ru) | 2005-09-26 | 2012-03-30 | Медарекс, Инк. | Человеческие моноклональные антитела к cd70 и их применение |
WO2007038868A2 (en) | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
CA2630483C (en) | 2005-12-08 | 2015-05-19 | Medarex, Inc. | Human monoclonal antibodies to o8e |
JP5512128B2 (ja) | 2005-12-08 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | フコシルgm1に対するヒトモノクローナル抗体および抗フコシルgm1を使用するための方法 |
SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
EP2001358B1 (en) | 2006-03-27 | 2016-07-13 | University Of Maryland, Baltimore | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
PE20080316A1 (es) | 2006-05-25 | 2008-04-10 | Bristol Myers Squibb Co | Compuestos de aziridinil-epotilona |
PE20080102A1 (es) | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos |
US8715958B2 (en) | 2006-06-29 | 2014-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free synthesis of proteins containing unnatural amino acids |
AU2007292891B2 (en) | 2006-09-08 | 2012-04-12 | Ambrx, Inc. | Site specific incorporation of non-natural amino acids by vertebrate cells |
ES2625798T3 (es) | 2006-10-02 | 2017-07-20 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
CN101626782B (zh) | 2006-12-01 | 2013-03-27 | 梅达雷克斯公司 | 结合cd22的人抗体及其用途 |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
CN101815726B (zh) | 2007-07-17 | 2013-04-03 | 米德列斯公司 | 针对磷脂酰肌醇蛋白聚糖-3的单克隆抗体 |
RS53760B1 (en) | 2007-10-01 | 2015-06-30 | Bristol-Myers Squibb Company | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
EA024118B1 (ru) | 2010-04-15 | 2016-08-31 | Сиэтл Дженетикс, Инк. | Конъюгаты пирролбензодиазепина направленного действия |
AU2011239525B2 (en) | 2010-04-15 | 2015-04-09 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
JP6099336B2 (ja) | 2011-09-14 | 2017-03-22 | 株式会社半導体エネルギー研究所 | 発光装置 |
AU2012311505B2 (en) | 2011-09-20 | 2016-09-29 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
EP3539982A3 (en) | 2011-12-23 | 2020-01-15 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
PE20141791A1 (es) | 2012-02-13 | 2014-11-19 | Bristol Myers Squibb Co | Compuestos de enediino, conjugados de los mismos y sus usos y metodos |
ES2611788T3 (es) * | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
DK2953976T3 (da) | 2013-02-08 | 2021-06-21 | Novartis Ag | Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater |
MX356698B (es) | 2013-02-14 | 2018-06-11 | Bristol Myers Squibb Co | Compuestos de tubulisina, metodos para obtenerlos y uso. |
AU2014306592B2 (en) | 2013-08-14 | 2019-04-04 | Bristol-Myers Squibb Company | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
CN106659800A (zh) | 2014-03-12 | 2017-05-10 | 诺华股份有限公司 | 用于修饰抗体以制备免疫缀合物的特定位点 |
PT3129406T (pt) | 2014-04-11 | 2019-04-24 | Medimmune Llc | Compostos conjugados que compreendem anticorpos com manipulação de cisteínas |
US10077318B2 (en) | 2014-09-12 | 2018-09-18 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
BR112017006602A2 (pt) | 2014-10-01 | 2017-12-19 | Medimmune Llc | método de conjugação de um polipeptídeo |
-
2016
- 2016-12-20 CA CA3008678A patent/CA3008678A1/en not_active Abandoned
- 2016-12-20 BR BR112018012524A patent/BR112018012524A2/pt not_active IP Right Cessation
- 2016-12-20 CN CN201680074829.3A patent/CN108431034A/zh active Pending
- 2016-12-20 EP EP16831861.6A patent/EP3394096A1/en not_active Withdrawn
- 2016-12-20 MX MX2018007479A patent/MX2018007479A/es unknown
- 2016-12-20 SG SG11201805150QA patent/SG11201805150QA/en unknown
- 2016-12-20 KR KR1020187017197A patent/KR20180089433A/ko unknown
- 2016-12-20 US US16/061,646 patent/US20180362619A1/en not_active Abandoned
- 2016-12-20 JP JP2018551898A patent/JP2019505575A/ja active Pending
- 2016-12-20 EA EA201891482A patent/EA201891482A1/ru unknown
- 2016-12-20 WO PCT/US2016/067663 patent/WO2017112624A1/en active Application Filing
- 2016-12-20 AU AU2016377371A patent/AU2016377371A1/en not_active Abandoned
-
2018
- 2018-06-14 IL IL260049A patent/IL260049A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL260049A (en) | 2018-07-31 |
AU2016377371A1 (en) | 2018-08-09 |
SG11201805150QA (en) | 2018-07-30 |
JP2019505575A (ja) | 2019-02-28 |
CA3008678A1 (en) | 2017-06-29 |
EP3394096A1 (en) | 2018-10-31 |
EA201891482A1 (ru) | 2018-12-28 |
MX2018007479A (es) | 2018-08-01 |
KR20180089433A (ko) | 2018-08-08 |
CN108431034A (zh) | 2018-08-21 |
US20180362619A1 (en) | 2018-12-20 |
WO2017112624A1 (en) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
UY37278A (es) | Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos | |
CL2018000920A1 (es) | Conjugados de anticuerpos que comprenden agonistas de receptor similares | |
CO2018005436A2 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
CL2018001000A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr. | |
CO2018001624A2 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
MX2017011281A (es) | Conjugados de amatoxina y anticuerpos. | |
BR112016025291A2 (pt) | conjugados de anticorpo anti-ptk7-fármaco | |
CL2016000465A1 (es) | Métodos de conjugación de anticuerpos específicos de sitio y composiciones. | |
PE20150892A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
EA201591465A1 (ru) | Специфичные участки для модификации антител для получения иммуноконъюгатов | |
CL2016002667A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
BR112017001588A2 (pt) | conjugados de anticorpo/fármaco anti-cdh6 | |
BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
BR112018075644A2 (pt) | anticorpos anti-cd98 e conjugados de anticorpo e fármaco | |
EA201591137A1 (ru) | Ингибиторы mk2 и их применения | |
CO2018005433A2 (es) | Conjugados de fármaco de anticuerpo her2 específicos de sitio | |
CO2017003005A2 (es) | Anticuerpos anti-mfi2 | |
BR112018012524A2 (pt) | anticorpos variantes para conjugação sítio-específica | |
BR112017006602A2 (pt) | método de conjugação de um polipeptídeo | |
BR112016023503A2 (pt) | arranjo de pista | |
CU20170012A7 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
EA201591709A1 (ru) | 5-бром-индирубины |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2555 DE 24/12/2019. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |